Demographics and baseline characteristics
| Characteristic . | All patients (N = 110) . |
|---|---|
| Age, median (range), y | 8.5 (0.4-17.0) |
| Age group, y, n (%) | |
| 0-1 | 13 (12) |
| 2-6 | 31 (28) |
| 7-17 | 66 (60) |
| Sex, n (%) | |
| Male | 62 (56) |
| Blast category, n (%) | |
| <5% with MRD ≥ 10−3 | 12 (11) |
| 5%-49% | 55 (50) |
| ≥50% | 42 (38) |
| Unknown | 1 (1) |
| Recurrent genetic abnormalities,* n (%) | |
| MLL rearrangement | 18† (16) |
| t(9;22)/BCR-ABL | 5 (5) |
| t(17;19) | 2 (2) |
| t(12;21)/TEL-AML1 | 9 (8) |
| Hypo/hyperdiploidy | 1 (1)/6 (5) |
| Other | 12 (11) |
| Constitutional trisomy 21 (Down syndrome), n (%) | 4 (4) |
| Prior therapy, n (%) | |
| alloHSCT | 45‡ (41) |
| Blinatumomab | 5 (5) |
| Disease history, n (%) | |
| Primary refractory disease | 17 (15) |
| Refractory to reinduction therapy | 23 (21) |
| Second or further relapse | 61 (55) |
| Relapse after alloHSCT | 44 (40) |
| Characteristic . | All patients (N = 110) . |
|---|---|
| Age, median (range), y | 8.5 (0.4-17.0) |
| Age group, y, n (%) | |
| 0-1 | 13 (12) |
| 2-6 | 31 (28) |
| 7-17 | 66 (60) |
| Sex, n (%) | |
| Male | 62 (56) |
| Blast category, n (%) | |
| <5% with MRD ≥ 10−3 | 12 (11) |
| 5%-49% | 55 (50) |
| ≥50% | 42 (38) |
| Unknown | 1 (1) |
| Recurrent genetic abnormalities,* n (%) | |
| MLL rearrangement | 18† (16) |
| t(9;22)/BCR-ABL | 5 (5) |
| t(17;19) | 2 (2) |
| t(12;21)/TEL-AML1 | 9 (8) |
| Hypo/hyperdiploidy | 1 (1)/6 (5) |
| Other | 12 (11) |
| Constitutional trisomy 21 (Down syndrome), n (%) | 4 (4) |
| Prior therapy, n (%) | |
| alloHSCT | 45‡ (41) |
| Blinatumomab | 5 (5) |
| Disease history, n (%) | |
| Primary refractory disease | 17 (15) |
| Refractory to reinduction therapy | 23 (21) |
| Second or further relapse | 61 (55) |
| Relapse after alloHSCT | 44 (40) |